These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 7338557

  • 21. A controlled study on the antihypertensive effect of a new beta-adrenergic receptor blocking drug, metoprolol, in combination with chlorthalidone.
    Jäättelä A, Pyörälä K.
    Br J Clin Pharmacol; 1976 Aug; 3(4):655-60. PubMed ID: 22216509
    [Abstract] [Full Text] [Related]

  • 22. Comparison of single-dose pharmacokinetic and pharmacodynamic properties of two metoprolol Oros systems with different initial zero-order release rates.
    Warrington SJ, Barclay SP, John VA, Shotton PA, Good W.
    Br J Clin Pharmacol; 1985 Aug; 19 Suppl 2(Suppl 2):225S-230S. PubMed ID: 4005127
    [Abstract] [Full Text] [Related]

  • 23. [Double-blind comparative study of the hypotensive effect of combination therapy with chlorthalidone and metoprolol or alpha-methyldopa].
    Guidi G, Giuntoli F, Galeone F, Checchi M, Locci P, Saba GC, Saba P.
    G Clin Med; 1981 Aug; 62(8):558-66. PubMed ID: 7030853
    [No Abstract] [Full Text] [Related]

  • 24. Angiotensin-converting enzyme inhibition and the combination of a beta blocker and a diuretic are equally effective in lowering proteinuria in patients with glomerulonephritis.
    Kloke HJ, Wetzels JF, van Hamersvelt HW, Koene RA, Huysmans FT.
    Nephrol Dial Transplant; 1993 Aug; 8(9):808-13. PubMed ID: 8255512
    [Abstract] [Full Text] [Related]

  • 25. Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function.
    Jordö L, Attman PO, Aurell M, Johansson L, Johnsson G, Regårdh CG.
    Clin Pharmacokinet; 1980 Aug; 5(2):169-80. PubMed ID: 6102500
    [Abstract] [Full Text] [Related]

  • 26. Hemodynamic effects of once a day administration of combined chlorthalidone and metoprolol slow-release in essential hypertension.
    Pomidossi G, Parati G, Motolese M, Mancia G, Zanchetti A.
    Int J Clin Pharmacol Ther Toxicol; 1984 Dec; 22(12):665-71. PubMed ID: 6526542
    [Abstract] [Full Text] [Related]

  • 27. A controlled study on the anti-hypertensive effect of a new beta-adrenoreceptor-blocking drug, metoprolol, in combination with chlorthalidone.
    Jäättelä A, Pyörälä K.
    Clin Sci Mol Med Suppl; 1976 Dec; 3():521s-523s. PubMed ID: 799561
    [Abstract] [Full Text] [Related]

  • 28. Age and responses to isometric exercise in hypertension: possible predictors of the antihypertensive effect of diuretics and beta-blockers.
    Corea L, Valori C, Bentivoglio M, Verdecchia P, Bichisao E.
    Int J Clin Pharmacol Ther Toxicol; 1985 Oct; 23(10):554-9. PubMed ID: 2866164
    [Abstract] [Full Text] [Related]

  • 29. [Use of metoprolol and atenolol, singly or in combination with a diuretic, in the treatment of arterial hypertension].
    Centritto V.
    Boll Soc Ital Cardiol; 1980 Oct; 25(5):451-7. PubMed ID: 7284149
    [No Abstract] [Full Text] [Related]

  • 30. Pharmacokinetics of atenolol in hypertensive subjects with and without co-administration of chlorthalidone.
    Riva E, Farina PL, Sega R, Tognoni G, Bastain W, McAinsh J.
    Eur J Clin Pharmacol; 1980 May; 17(5):333-7. PubMed ID: 7418712
    [Abstract] [Full Text] [Related]

  • 31. Plasma levels and negative chronotropic effect of metoprolol following single doses of a conventional and sustained-release formulation.
    Quaterman CP, Kendall MJ, Welling PG.
    Eur J Clin Pharmacol; 1979 Mar 26; 15(2):97-103. PubMed ID: 436924
    [Abstract] [Full Text] [Related]

  • 32. Total body potassium in patients receiving chlorthalidone and metoprolol for hypertension.
    Gray JM, Lawson DH, Boddy K, East W.
    Scott Med J; 1983 Apr 26; 28(2):172-5. PubMed ID: 6867699
    [Abstract] [Full Text] [Related]

  • 33. Bioavailability in man of atenolol and chlorthalidone from a combination formulation.
    McAinsh J, Bastain W, Young J, Harry JD.
    Biopharm Drug Dispos; 1981 Apr 26; 2(2):147-56. PubMed ID: 7248478
    [Abstract] [Full Text] [Related]

  • 34. Effect of rifampicin on metoprolol and antipyrine kinetics.
    Bennett PN, John VA, Whitmarsh VB.
    Br J Clin Pharmacol; 1982 Mar 26; 13(3):387-91. PubMed ID: 7059439
    [Abstract] [Full Text] [Related]

  • 35. A multiple dose pharmacokinetic and pharmacodynamic evaluation of conventional and 19/285 Oros formulations of metoprolol in healthy volunteers.
    Grainger SL, John VA, Shotton PA, Smith SE.
    Br J Clin Pharmacol; 1985 Mar 26; 19 Suppl 2(Suppl 2):239S-244S. PubMed ID: 4005129
    [Abstract] [Full Text] [Related]

  • 36. Oros controlled-release formulations of metoprolol: an approach to the development of a system for once daily administration.
    Good W, Leeson LJ, Zak SL, Wagner WE, Meeker JB, Arnold JD.
    Br J Clin Pharmacol; 1985 Mar 26; 19 Suppl 2(Suppl 2):231S-238S. PubMed ID: 4005128
    [Abstract] [Full Text] [Related]

  • 37. Controlled release metoprolol. Clinical pharmacokinetic and therapeutic implications.
    Kendall MJ, Maxwell SR, Sandberg A, Westergren G.
    Clin Pharmacokinet; 1991 Nov 26; 21(5):319-30. PubMed ID: 1773547
    [Abstract] [Full Text] [Related]

  • 38. Metoprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders.
    Benfield P, Clissold SP, Brogden RN.
    Drugs; 1986 May 26; 31(5):376-429. PubMed ID: 2940080
    [Abstract] [Full Text] [Related]

  • 39. The comparative beta-adrenoceptor blocking effects of penbutolol, atenolol and sustained-release metoprolol in healthy volunteers.
    Mucklow JC, Kuhn S.
    Eur J Clin Pharmacol; 1984 May 26; 27(3):269-73. PubMed ID: 6510453
    [Abstract] [Full Text] [Related]

  • 40. The pharmacodynamic and pharmacokinetic profiles of controlled-release formulations of felodipine and metoprolol in free and fixed combinations in elderly hypertensive patients.
    McLay JS, MacDonald TM, Hosie J, Elliott HL, Logimax Group.
    Eur J Clin Pharmacol; 2000 Nov 26; 56(8):529-35. PubMed ID: 11151741
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.